Nevakar and Théa Enter into Licensing Agreement for the Commercialization of NVK-002 (Atropine for the Treatment of the Progression of Myopia in Children) in Europe
— Potential to receive up to $135 million upon the successful attainment of several key…
Shook & Stone Opens Up “An Ideal Lawyer’s Portrait: Representation Matters” 2026 Scholarship
Marketing 1on1 Announces the Addition of Local Citations to Its Backlink Service Offerings
Think Business, Think Hong Kong strengthens Italy-Hong Kong ties and opens new path for Asian collaboration
FUTR Announces Q1 2026 Financial Results